Sint-Lambrechts-Woluwe

• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting
  2024-517432-21-00 4 2025-05-30 Gynecological Cancers
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 Diffuse Large B-Cell Lymphoma (DLBCL)
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer Recruiting
  2024-516615-25-00 1 2025-05-14 hepatocellular carcinoma (HCC)
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa … Recruiting
  2024-516030-35-00 5 2025-04-30 Multiple myeloma
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido … Recruiting
  2024-515279-37-00 5 2025-04-17 Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Recruiting
  2023-504904-26-00 5 2025-04-07 Progressive Pulmonary Fibrosis
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem … Recruiting
  2023-505773-32-00 10 2025-03-25 Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing st … Recruiting
  2022-501315-13-00 5 2025-03-06 Patients with lateralised oropharyngeal, laryngeal and hypopharyngeal
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después … Recruiting
  2023-508741-40-00 10 2025-01-14 Non-small cell lung cancer
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy

Showing 169–192 of 635 trials